In the first half of 2025, the innovative drug sector of the Hong Kong stock market made great strides, driven by factors such as policy, industry catalyst, market sentiment, etc., and the performance of active equity funds that heavily invested in individual stocks in related sectors advanced by leaps and bounds in the first half of the year. Huitianfu Hong Kong Advantage Select A has a return of over 85%, and many other products have a return of over 60%. As sector valuations reached a relatively high level, the market was divided in its judgment on subsequent market conditions. Some institutions believe that short-term incident catalysis has come to an end, short-term trading funds may choose to end profitably, and stock price adjustments will also release certain risks. Investors need to carefully screen the attributes of the corresponding assets, especially considering the company's ability to deliver on performance.

In the first half of 2025, the innovative drug sector of the Hong Kong stock market made great strides, driven by factors such as policy, industry catalyst, market sentiment, etc., and the performance of active equity funds that heavily invested in individual stocks in related sectors advanced by leaps and bounds in the first half of the year. Huitianfu Hong Kong Advantage Select A has a return of over 85%, and many other products have a return of over 60%. As sector valuations reached a relatively high level, the market was divided in its judgment on subsequent market conditions. Some institutions believe that short-term incident catalysis has come to an end, short-term trading funds may choose to end profitably, and stock price adjustments will also release certain risks. Investors need to carefully screen the attributes of the corresponding assets, especially considering the company's ability to deliver on performance.